Silverfin false false 31/03/2024 01/04/2023 31/03/2024 R Misra 04/02/2022 R Yarlagadda 04/02/2022 Dr R Yarlagadda 21 October 2024 The principal activity of the company during the financial year was that of the provision of medical services. 13894090 2024-03-31 13894090 bus:Director1 2024-03-31 13894090 bus:Director2 2024-03-31 13894090 2023-03-31 13894090 core:CurrentFinancialInstruments 2024-03-31 13894090 core:CurrentFinancialInstruments 2023-03-31 13894090 core:ShareCapital 2024-03-31 13894090 core:ShareCapital 2023-03-31 13894090 core:RetainedEarningsAccumulatedLosses 2024-03-31 13894090 core:RetainedEarningsAccumulatedLosses 2023-03-31 13894090 core:OfficeEquipment 2023-03-31 13894090 core:OfficeEquipment 2024-03-31 13894090 bus:OrdinaryShareClass1 2024-03-31 13894090 bus:OrdinaryShareClass2 2024-03-31 13894090 bus:OrdinaryShareClass3 2024-03-31 13894090 bus:OrdinaryShareClass4 2024-03-31 13894090 2023-04-01 2024-03-31 13894090 bus:FilletedAccounts 2023-04-01 2024-03-31 13894090 bus:SmallEntities 2023-04-01 2024-03-31 13894090 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 13894090 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 13894090 bus:Director1 2023-04-01 2024-03-31 13894090 bus:Director2 2023-04-01 2024-03-31 13894090 bus:Director3 2023-04-01 2024-03-31 13894090 core:OfficeEquipment core:TopRangeValue 2023-04-01 2024-03-31 13894090 2022-02-04 2023-03-31 13894090 core:OfficeEquipment 2023-04-01 2024-03-31 13894090 bus:OrdinaryShareClass1 2023-04-01 2024-03-31 13894090 bus:OrdinaryShareClass1 2022-02-04 2023-03-31 13894090 bus:OrdinaryShareClass2 2023-04-01 2024-03-31 13894090 bus:OrdinaryShareClass2 2022-02-04 2023-03-31 13894090 bus:OrdinaryShareClass3 2023-04-01 2024-03-31 13894090 bus:OrdinaryShareClass3 2022-02-04 2023-03-31 13894090 bus:OrdinaryShareClass4 2023-04-01 2024-03-31 13894090 bus:OrdinaryShareClass4 2022-02-04 2023-03-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 13894090 (England and Wales)

RY ORTHOPAEDICS LIMITED

Unaudited Financial Statements
For the financial year ended 31 March 2024
Pages for filing with the registrar

RY ORTHOPAEDICS LIMITED

Unaudited Financial Statements

For the financial year ended 31 March 2024

Contents

RY ORTHOPAEDICS LIMITED

BALANCE SHEET

As at 31 March 2024
RY ORTHOPAEDICS LIMITED

BALANCE SHEET (continued)

As at 31 March 2024
Note 31.03.2024 31.03.2023
£ £
Fixed assets
Tangible assets 3 3,053 2,918
3,053 2,918
Current assets
Debtors 4 2,943 6,724
Cash at bank and in hand 37,488 21,259
40,431 27,983
Creditors: amounts falling due within one year 5 ( 7,796) ( 7,578)
Net current assets 32,635 20,405
Total assets less current liabilities 35,688 23,323
Net assets 35,688 23,323
Capital and reserves
Called-up share capital 6 100 100
Profit and loss account 35,588 23,223
Total shareholders' funds 35,688 23,323

For the financial year ending 31 March 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of RY Orthopaedics Limited (registered number: 13894090) were approved and authorised for issue by the Board of Directors on 21 October 2024. They were signed on its behalf by:

Dr R Yarlagadda
Director
RY ORTHOPAEDICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2024
RY ORTHOPAEDICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial period, unless otherwise stated.

General information and basis of accounting

RY Orthopaedics Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is C/O Francis Clark Llp Unit 18, 23 Melville Building East, Royal William Yard, Plymouth, PL1 3GW, United Kingdom. The principle place of business for the company is: Plymouth Hospital, Derriford Road, Plymouth, PL6 8BG.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Turnover

Turnover on medical services performed is stated net of VAT and is recognised as and when the services themselves have been performed.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on tax rates and laws substantively enacted at the balance sheet date. Deferred tax assets and liabilities are not discounted.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a [straight-line, reducing balance] basis over its expected useful life, as follows:

Office equipment 3 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets receivable within one year, such as trade debtors and bank balances, are measured at transaction price less any impairment.

Basic financial assets receivable within more than one year are measured at amortised cost less any impairment.

Financial assets are derecognised when and only when the contractual rights to the cash flows from the financial asset expire or are settled, or the Company transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or the Company, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Basic financial liabilities
Basic financial liabilities that have no stated interest rate and are payable within one year, such as trade creditors, are measured at transaction price.

Other basic financial liabilities are measured at amortised cost.

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

2. Employees

Year ended
31.03.2024
Period from
04.02.2022 to
31.03.2023
Number Number
Monthly average number of persons employed by the Company during the year, including directors 0 0

3. Tangible assets

Office equipment Total
£ £
Cost
At 01 April 2023 2,918 2,918
Additions 1,286 1,286
At 31 March 2024 4,204 4,204
Accumulated depreciation
At 01 April 2023 0 0
Charge for the financial year 1,151 1,151
At 31 March 2024 1,151 1,151
Net book value
At 31 March 2024 3,053 3,053
At 31 March 2023 2,918 2,918

4. Debtors

31.03.2024 31.03.2023
£ £
Trade debtors 0 6,300
Amounts owed by directors 2,943 424
2,943 6,724

5. Creditors: amounts falling due within one year

31.03.2024 31.03.2023
£ £
Accruals 1,970 1,800
Taxation and social security 5,817 5,778
Other creditors 9 0
7,796 7,578

6. Called-up share capital

31.03.2024 31.03.2023
£ £
Allotted, called-up and fully-paid
8 Ordinary A shares of £ 1.00 each 8 8
46 Ordinary B shares of £ 1.00 each 46 46
23 Ordinary C shares of £ 1.00 each 23 23
23 Ordinary D shares of £ 1.00 each 23 23
100 100

7. Related party transactions

Transactions with the entity's directors

31.03.2024 31.03.2023
£ £
Directors' Loan Account 2,943 424

Advances

During the period the Company operated a loan account with Directors 1 and 2. The Company advanced £15,327 (2023: £6,200) to them, of which £12,808 (2023: £5,776) was repaid. Interest was not charged on this loan and the loan is repayable on demand. the balance owed by the directors at 31 March 2024 was £2,943.